Literature DB >> 21344998

Survival and clinical features in Hispanic amyotrophic lateral sclerosis patients.

Héctor R Martínez1, Juan Francisco Molina-López, Leonel Cantú-Martínez, María Teresa González-Garza, Jorge E Moreno-Cuevas, Patricio Couret-Alcaraz, Sergio A Treviño, Yenny Webb-Vargas, Enrique Caro, Alfonso Gil-Valadez, Jesús Santos-Guzmán, Martin Hernandez-Torre.   

Abstract

The demography, survival, and motor phenotypes of amyotrophic lateral sclerosis (ALS) patients have been rarely described in Hispanic countries. The clinical characteristics and survival of a series of Mexican ALS patients are described. Mexican patients with definite ALS were included in a five-year retrospective longitudinal study. Their demographic and clinical features, cumulative survival rates, and independent predictive factors for survival were analysed. Sixty-one definite ALS patients were included. The median follow-up period was 35 months (range 12-108 months). Males were predominant (1.8: 1), the mean age at onset was 47.5 ± 10.5 years, and the median interval from onset to diagnosis was 12 months. Spinal onset occurred in 66% of patients. Upper motor neuron phenotype was predominant in 53% of patients. The overall mean survival from onset was 68.6 months, and from diagnosis was 57.8 months. Longer survival was determined in patients aged ≤ 40 years (54.7 months) compared with other age groups (p = 0.006). In conclusion, the clinical heterogeneity, male predominance, and survival rates in our sample are consistent with those of other studies. Patients in this series had a younger age at onset and a clear trend toward longer survival compared with those of other population studies.

Entities:  

Mesh:

Year:  2011        PMID: 21344998     DOI: 10.3109/17482968.2010.550302

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  6 in total

1.  Stratification of ALS patients' survival: a population-based study.

Authors:  Benoît Marin; Philippe Couratier; Simona Arcuti; Massimiliano Copetti; Andrea Fontana; Marie Nicol; Marie Raymondeau; Giancarlo Logroscino; Pierre Marie Preux
Journal:  J Neurol       Date:  2015-10-30       Impact factor: 4.849

2.  Label-Free LC-MS/MS Proteomic Analysis of Cerebrospinal Fluid Identifies Protein/Pathway Alterations and Candidate Biomarkers for Amyotrophic Lateral Sclerosis.

Authors:  Mahlon A Collins; Jiyan An; Brian L Hood; Thomas P Conrads; Robert P Bowser
Journal:  J Proteome Res       Date:  2015-10-08       Impact factor: 4.466

3.  Differentiation of CD133+ stem cells from amyotrophic lateral sclerosis patients into preneuron cells.

Authors:  Maria Teresa González-Garza; Héctor R Martínez; Enrique Caro-Osorio; Delia E Cruz-Vega; Martin Hernández-Torre; Jorge E Moreno-Cuevas
Journal:  Stem Cells Transl Med       Date:  2013-01-22       Impact factor: 6.940

4.  Aberration of miRNAs Expression in Leukocytes from Sporadic Amyotrophic Lateral Sclerosis.

Authors:  YongPing Chen; QianQian Wei; XuePing Chen; ChunYu Li; Bei Cao; RuWei Ou; Shinji Hadano; Hui-Fang Shang
Journal:  Front Mol Neurosci       Date:  2016-08-17       Impact factor: 5.639

5.  Riluzole and prognostic factors in amyotrophic lateral sclerosis long-term and short-term survival: a population-based study of 1149 cases in Taiwan.

Authors:  Charles Tzu-Chi Lee; Yi-Wen Chiu; Kai-Chen Wang; Chi-Shin Hwang; Kuan-Hsiang Lin; I-Ta Lee; Ching-Piao Tsai
Journal:  J Epidemiol       Date:  2012-10-27       Impact factor: 3.211

6.  A retrospective study of the clinical phenotype and predictors of survival in non-Caucasian Hispanic patients with amyotrophic lateral sclerosis.

Authors:  Claudia Marisol Sánchez-Martínez; José Alberto Choreño-Parra; Lilia Nuñez-Orozco; Noel Placencia-Álvarez; Laura Marcela Alvis-Castaño; Parménides Guadarrama-Ortiz
Journal:  BMC Neurol       Date:  2019-10-29       Impact factor: 2.474

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.